- Home
- ANSC vs ADCT Comparison
ANSC vs ADCT Comparison
Compare ANSC & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ANSC | ADCT |
|---|---|---|
| Founded | 2021 | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 467.0M | 484.4M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | ANSC | ADCT |
|---|---|---|
| Price | $11.24 | $4.10 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | 17.1K | ★ 812.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 44.90 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $70,837,000.00 |
| Revenue This Year | N/A | $14.96 |
| Revenue Next Year | N/A | $1.06 |
| P/E Ratio | $55.07 | ★ N/A |
| Revenue Growth | N/A | ★ 1.84 |
| 52 Week Low | $10.57 | $1.05 |
| 52 Week High | $11.24 | $4.80 |
Technical Indicators
Market Signals| Indicator | ANSC | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 60.67 | 51.41 |
| Support Level | $11.15 | $3.25 |
| Resistance Level | $11.24 | $4.71 |
| Average True Range (ATR) | 0.01 | 0.25 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 100.00 | 29.76 |
Price Performance
Historical ComparisonAbout ANSC Agriculture & Natural Solutions Acquisition Corporation
Agriculture & Natural Solutions Acquisition Corp is a blank check company.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).